

# Masahiko Shimura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/218322/publications.pdf>

Version: 2024-02-01

58  
papers

1,454  
citations

430754

18  
h-index

360920

35  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1208  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 579-592.	0.9	2
2	Treatment of diabetic macular edema in real-world clinical practice: the effect of aging. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	2
3	RELATIONSHIP BETWEEN CHOROIDAL FINDINGS AND GROWTH FACTORS, CYTOKINES, AND OTHER INFLAMMATORY MEDIATORS AFTER INTRAVITREAL RANIBIZUMAB INJECTION IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2022, 42, 744-751.	1.0	3
4	Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. <i>European Journal of Ophthalmology</i> , 2021, 31, 204-210.	0.7	12
5	Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema. <i>Ophthalmic Research</i> , 2021, 64, 43-49.	1.0	19
6	Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3427.	1.8	47
7	Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 2597-2603.	1.0	5
8	Efficacy-Based Aflibercept Treatment Regimen for Central Retinal Vein Occlusion. <i>Ophthalmology Retina</i> , 2021, 5, 1177-1179.	1.2	3
9	Role of ICAM-1 in impaired retinal circulation in rhegmatogenous retinal detachment. <i>Scientific Reports</i> , 2021, 11, 15393.	1.6	2
10	Retinal Blood Flow as a Predictor of Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion. <i>Ophthalmic Research</i> , 2021, 64, 1013-1019.	1.0	2
11	Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, , 1.	1.0	8
12	Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion. <i>Journal of Clinical Medicine</i> , 2021, 10, 58.	1.0	7
13	Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study. <i>British Journal of Ophthalmology</i> , 2020, 104, bjophthalmol-2019-315199.	2.1	19
14	Cytokines and Pathogenesis of Central Retinal Vein Occlusion. <i>Journal of Clinical Medicine</i> , 2020, 9, 3457.	1.0	43
15	Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema. <i>Scientific Reports</i> , 2020, 10, 21713.	1.6	4
16	Functional and anatomical changes in diabetic macular edema after hemodialysis initiation: One-year follow-up multicenter study. <i>Scientific Reports</i> , 2020, 10, 7788.	1.6	18
17	Relationship between retinal blood flow and cytokines in central retinal vein occlusion. <i>BMC Ophthalmology</i> , 2020, 20, 215.	0.6	13
18	Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention <i>from STREAT-DMO study</i>. <i>British Journal of Ophthalmology</i> , 2020, 104, 1755-1761.	2.1	11

#	ARTICLE	IF	CITATIONS
19	Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema. <i>Ophthalmic Research</i> , 2019, 61, 210-217.	1.0	13
20	Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2019, 241, 81-89.	1.0	27
21	Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 407-412.	0.6	11
22	Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion. <i>Journal of Inflammation</i> , 2019, 16, 9.	1.5	5
23	Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-9.	0.6	44
24	Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. <i>Ophthalmologica</i> , 2019, 241, 161-169.	1.0	8
25	Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2018, 102, 1351-1357.	2.1	16
26	Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration. <i>Journal of Inflammation</i> , 2018, 15, 26.	1.5	6
27	Functional morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab. <i>British Journal of Ophthalmology</i> , 2017, 101, 180-185.	2.1	18
28	Changes of retinal flow volume after intravitreal injection of bevacizumab in branch retinal vein occlusion with macular edema: a case series. <i>BMC Ophthalmology</i> , 2016, 16, 61.	0.6	10
29	Comparative Effects of Topical Diclofenac and Betamethasone on Inflammation After Vitrectomy and Cataract Surgery in Various Vitreoretinal Diseases. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 677-684.	0.6	11
30	Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. <i>Japanese Journal of Ophthalmology</i> , 2016, 60, 401-407.	0.9	18
31	Role of Soluble Vascular Endothelial Growth Factor Receptor Signaling and Other Factors or Cytokines in Central Retinal Vein Occlusion With Macular Edema. <i>Investigative Ophthalmology and Visual Science</i> , 2015, 56, 1122-1128.	3.3	51
32	Photopic negative response in branch retinal vein occlusion with macular edema. <i>International Ophthalmology</i> , 2015, 35, 19-26.	0.6	11
33	Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. <i>British Journal of Ophthalmology</i> , 2015, 99, 215-219.	2.1	14
34	Relationship of Skin Autofluorescence to Severity of Retinopathy in Type 2 Diabetes. <i>Current Eye Research</i> , 2015, 40, 338-345.	0.7	29
35	Relative Flow Volume, a Novel Blood Flow Index in the Human Retina Derived From Laser Speckle Flowgraphy. , 2014, 55, 3899.		58
36	Role of Inflammation in Diabetic Macular Edema. <i>Ophthalmologica</i> , 2014, 232, 127-135.	1.0	56

#	ARTICLE	IF	CITATIONS
37	Role of Soluble Vascular Endothelial Growth Factor Receptors-1 and -2, Their Ligands, and Other Factors in Branch Retinal Vein Occlusion With Macular Edema. , 2014, 55, 3878.		52
38	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB DEPENDS ON THE OPTICAL COHERENCE TOMOGRAPHIC PATTERNS OF PATIENTS WITH DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2013, 33, 740-747.	1.0	88
39	A Comparison of Preservative-Free Diclofenac and Preserved Diclofenac Eye Drops after Cataract Surgery in Patients with Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 283-289.	0.6	13
40	Pre-seasonal Treatment With Topical Olopatadine Suppresses the Clinical Symptoms of Seasonal Allergic Conjunctivitis. <i>American Journal of Ophthalmology</i> , 2011, 151, 697-702.e2.	1.7	10
41	EARLY CHANGE OF CENTRAL MACULAR THICKNESS AFTER INTRAVITREOUS TRIAMCINOLONE OR BEVACIZUMAB IN DIABETIC MACULAR EDEMA OR RETINAL VEIN OCCLUSION. <i>Retina</i> , 2011, 31, 290-297.	1.0	13
42	VISUAL OUTCOME AFTER INTRAVITREAL TRIAMCINOLONE ACETONIDE DEPENDS ON OPTICAL COHERENCE TOMOGRAPHIC PATTERNS IN PATIENTS WITH DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2011, 31, 748-754.	1.0	57
43	Drug reflux during posterior subtenon infusion of triamcinolone acetonide in diffuse diabetic macular edema not only brings insufficient reduction but also causes elevation of intraocular pressure. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 907-912.	1.0	12
44	Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1617-1624.	1.0	78
45	Diclofenac prevents temporal increase of intraocular pressure after uneventful cataract surgery with longer operation time. <i>Clinical Ophthalmology</i> , 2009, 3, 95-101.	0.9	3
46	Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema. <i>Acta Ophthalmologica</i> , 2008, 86, 377-384.	0.6	26
47	Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Persistent Diffuse Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2008, 145, 854-861.e3.	1.7	170
48	Understanding the mechanism of retinal detachment-induced photoreceptor apoptosis: neuroprotective treatments for photoreceptor apoptosis. <i>Inflammation and Regeneration</i> , 2008, 28, 522-528.	1.5	1
49	Diclofenac Prevents an Early Event of Macular Thickening After Cataract Surgery in Patients with Diabetes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2007, 23, 284-291.	0.6	26
50	Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2007, 91, 449-454.	2.1	33
51	Panretinal-Photocoagulation before Pars Plana Vitrectomy Influences Vitreous Level of Interleukin-6 but not of Vascular Endothelial Growth Factor in Patients with Diabetic Retinopathy. <i>International Journal of Biomedical Science</i> , 2007, 3, 31-7.	0.5	3
52	Posterior Subâ€“Tenonâ€™s Capsule Injection of Triamcinolone Acetonide Prevents Panretinal Photocoagulation-Induced Visual Dysfunction in Patients with Severe Diabetic Retinopathy and Good Vision. <i>Ophthalmology</i> , 2006, 113, 381-387.	2.5	37
53	The Effect of Unoprostone Isopropyl on Ca <sup>2+</sup> Releaseâ€“Activated Ca <sup>2+</sup> Currents in Cultured Monkey Trabecular Meshwork Cells and Ciliary Muscle Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2006, 22, 219-226.	0.6	8
54	Visual Dysfunction After Panretinal Photocoagulation in Patients With Severe Diabetic Retinopathy and Good Vision. <i>American Journal of Ophthalmology</i> , 2005, 140, 8.e1-8.e10.	1.7	45

#	ARTICLE	IF	CITATIONS
55	Effective treatment of diffuse diabetic macular edema by temporal grid pattern photocoagulation. <i>Ophthalmic Surgery, Lasers and Imaging</i> , 2004, 35, 270-80.	0.5	3
56	Choroiditis in Systemic Lupus Erythematosus: Systemic Steroid Therapy and Focal Laser Treatment. <i>Japanese Journal of Ophthalmology</i> , 2003, 47, 312-315.	0.9	18
57	Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. <i>Ophthalmology</i> , 2003, 110, 2386-2394.	2.5	116
58	Quantitative analysis of leukocyte dynamics in retinal microcirculation of rats with short-term ischemia-reperfusion injury. <i>Current Eye Research</i> , 1999, 19, 403-410.	0.7	16